AACT Antibody (F-10): sc-518261

AACT (F-10) is a mouse monoclonal IgG1 kappa light chain antibody that detects AACT of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF) and enzyme-linked immunosorbent assay (ELISA). Anti-AACT antibody (F-10) is available as non-conjugated form, as well as multiple conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC) and multiple Alexa Fluor® conjugates. The serine proteinase inhibitors (serpins) are a superfamily of proteins with diverse functions, including control of blood coagulation, complement activation, programmed cell death and development. The most abundant serpins in human plasma are a 1-antitrypsin (AAT) and a 1-antichymotrypsin (AACT). AACT (also called A1AC and SERPINA3) is a plasma protease inhibitor synthesized in the liver as a single glycopeptide chain. In humans, normal serum level of AACT is about one-tenth that of AAT, with which AACT shares nucleic acid and protein sequence homology. Both are major acute phase reactants; plasma concentrations increase in response to trauma, surgery and infection. Elevated levels of AACT are widely, but not universally, reported in cerebrospinal fluid and plasma of AD patients. Prostate-specific antigen (PSA) and PSA′s SDS-stable complex with AACT are in widespread use as markers for prostate cancer diagnosis. AACT deficiency may also be a possible cause of chronic liver disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

AACT Antibody (F-10) References:

1. Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer.  |  Hara, I., et al. 2001. BJU Int. 88: 53-7. PMID: 11446846
2. Inhibition of prostate-specific antigen (PSA) by alpha(1)-antichymotrypsin: salt-dependent activation mediated by a conformational change.  |  Hsieh, MC. and Cooperman, BS. 2002. Biochemistry. 41: 2990-7. PMID: 11863437
3. Role of alpha-1-antichymotrypsin deficiency in promoting cirrhosis in two siblings with heterozygous alpha-1-antitrypsin deficiency phenotype SZ.  |  Yoon, D., et al. 2002. Gut. 50: 730-2. PMID: 11950825
4. Distribution of plasma alpha 1-antichymotrypsin levels in Alzheimer disease patients and controls and their genetic controls.  |  Wang, X., et al. 2002. Neurobiol Aging. 23: 377-82. PMID: 11959399
5. Gene regulation of the serine proteinase inhibitors alpha1-antitrypsin and alpha1-antichymotrypsin.  |  Kalsheker, N., et al. 2002. Biochem Soc Trans. 30: 93-8. PMID: 12023832
6. Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe alpha1-antitrypsin deficiency.  |  Hollander, C., et al. 2007. BMC Pulm Med. 7: 1. PMID: 17261175
7. SERPINA3 (aka alpha-1-antichymotrypsin).  |  Baker, C., et al. 2007. Front Biosci. 12: 2821-35. PMID: 17485262
8. Systemic markers of inflammation and cognitive decline in old age.  |  Schram, MT., et al. 2007. J Am Geriatr Soc. 55: 708-16. PMID: 17493190
9. SERPINA3 in glioblastoma and Alzheimer's disease.  |  Norton, ES., et al. 2021. Aging (Albany NY). 13: 21812-21813. PMID: 34587119
10. Reactive astrocytes transduce inflammation in a blood-brain barrier model through a TNF-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin.  |  Kim, H., et al. 2022. Nat Commun. 13: 6581. PMID: 36323693
11. SERPINA3: Stimulator or Inhibitor of Pathological Changes.  |  de Mezer, M., et al. 2023. Biomedicines. 11: PMID: 36672665
12. Two consecutive dinucleotide repeats constitute an informative marker at the alpha 1-antichymotrypsin (AACT) locus.  |  Byth, BC. and Cox, DW. 1993. Hum Mol Genet. 2: 1085. PMID: 8364563

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-AACT Antibody (F-10) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-AACT Antibody (F-10) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

AACT Antibody (F-10) Specifications

Alternate Product Name: AACT

Product Clone Name: F-10

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 294-320

Epitope Target: AACT

Epitope Species: human

Product Reactivity/Detection: AACT

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for AACT Antibody (F-10): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin